MedTrace Logo

Novel Medication as a Potential Smoking Cessation Aid

NCT02265367 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-04-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.

Conditions

  • Tobacco Use Disorder

Interventions

DRUG

Levomilnacipran

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Michael Kotlyar, PharmD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02265367 on ClinicalTrials.gov